Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Bellicum Pharmaceuticals (BLCM) announced the grant of 70,000 stock options to a new employee, approved by its Compensation Committee, with an effective date of September 30, 2022. The options have an exercise price of $1.20 per share and will vest over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's commitment to attracting talent. Bellicum focuses on developing controllable cellular immunotherapies for cancer, enhancing CAR-T cell therapies through innovative technologies.

Positive

• Equity inducement grants of 70,000 stock options to attract new talent.
• Stock options have a favorable exercise price of $1.20 per share.
• Vesting schedule of stock options incentivizes long-term employee engagement.

Negative

• None.

HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) --  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 70,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of September 30, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $1.20 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. The stock options are subject to the terms and conditions of the Company's 2019 Equity Incentive Plan and a stock option agreement covering the grant.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T^® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.

Source: Bellicum Pharmaceuticals

Investors:

Robert H. Uhl
Managing Director
Westwicke IR
858-356-5932
Robert.uhl@westwicke.com

FAQ

What stock options were granted by Bellicum Pharmaceuticals on September 30, 2022?

Bellicum Pharmaceuticals granted 70,000 stock options to a new employee with an exercise price of $1.20 per share.

How long do the stock options for Bellicum Pharmaceuticals vest?

The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter.

What is the reason for the stock option grants at Bellicum Pharmaceuticals?

The stock options were granted as inducements material to the employee's entry into employment with the company.

Which Nasdaq rule was followed for Bellicum Pharmaceuticals' stock option grants?

The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

What type of therapies does Bellicum Pharmaceuticals focus on?

Bellicum specializes in developing controllable cellular immunotherapies for cancers.